AMAnna Gudrun Melchior

Anna Gudrun Melchior

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anna Gudrun Melchior has a total of 7 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Substance P Triggers Migraine Attacks without Aura: A Randomised, Double-Blind, Placebo-Controlled, Two-Way Crossover Human Experimental Study

    by Haidar Muhsen Al-Khazali, Rune Häckert Christensen, Anna Gudrun Melchior, Sarra Al-Khazali, Basit Ali Chaudhry, Messoud Ashina, Håkan Ashina

    Background: Substance P is a vasoactive neuropeptide implicated in trigeminovascular signalling, but its causal role in initiating migraine attacks remains uncertain. We tested whether intravenous infusion of substance P triggers migraine attacks in people with migraine without aura.Methods: This was a randomised, double-blind, placebo-controlled, single-centre, two-way crossover study involving adults with migraine without aura. Participants received intravenous substance P (4·0 pmol/kg/min for 20 min) and isotonic saline (placebo) in random order, separated by a 1-week washout. Randomisation was generated by an independent hospital pharmacy using block randomisation (block size four; final participant by simple randomisation). Participants, investigators, care providers, and outcome assessors were masked to allocation. The primary outcome was incidence of a migraine attack without aura within 12 h after infusion. The primary analysis used McNemar’s test for paired outcomes. Safety outcomes included adverse events and hemodynamic measures. This study was pre-registered with ClinicalTrials.gov (Identifier: NCT06959004).Findings: Between May 13 and Aug 17, 2025, 66 individuals were assessed for eligibility; 21 were enrolled and randomised (18 female and three male); all completed both sessions. Migraine attacks occurred in 17 of 21 participants (81%) following substance P and two (10%) after placebo (p < 0·001). Median time to migraine onset was 20 min (IQR 20–30) after substance P, and median peak headache intensity (0–10 numeric rating scale) was 5 (IQR 3–6). The area under the curve for headache intensity scores over 12 h was greater after substance P than placebo (p < 0·001). Eight participants required acute headache medication after substance P versus two after placebo. No serious adverse events occurred.Interpretation: Intravenous substance P triggers migraine attacks in adults with migraine without aura, supporting a causal role for substance P-related signalling in attack initiation and motivating identification of this pathway as a potential therapeutic target.

  • Open Access

    Epidemiology and clinical features of occipital neuralgia: A systematic review and meta-analysis

    by Anna G. Melchior, Sarra Al-Khazali, Rune H. Christensen, Haidar M. Al-Khazali, Håkan Ashina

    Background: Occipital neuralgia (ON) describes severe, paroxysmal occipital nerve pain. This review synthesizes data on the epidemiology and clinical features of ON. Methods: A systematic search of PubMed and Embase databases was conducted from 1988 to 2024. Two investigators independently screened titles, abstracts and full-text articles, and conducted a risk of bias assessment. Meta-analyses were performed using a random-effects model, and between-study heterogeneity was assessed using the I² statistic. Results: Fifteen clinic-based studies, comprising 579 patients with ON, were eligible. No population-based studies were identified. Of these, three clinic-based studies examined the relative frequency of ON among adults evaluated for headache or facial pain, with reported rates ranging from 0.6 to 24.4%. Pooled estimates revealed that ON presents in the fifth decade of life and afflicts females (73%). Common clinical features were unilateral pain (81%), a stabbing quality (59%) and severe intensity (54%). Pain affected the greater occipital nerve (98%) with accompanying hypoesthesia (73%). A history of co-existing migraine was common (46%) and a proportion had a history of neck trauma (30%). The between-study heterogeneity was considerable for most clinical features assessed. Conclusions: ON shows female predominance and links with migraine and neck trauma. Identified features can aid diagnosis and management, but high heterogeneity calls for population-based research to clarify the epidemiology of ON. Trial Registration: PROSPERO (identifier: CRD42024539063).